Cardiolynx ^Company

Cardiolynx focuses on novel treatments for cardio-metabolic diseases, a broad therapeutic area with high unmet medical need and significant growth potential. Cardiolynx’ builds upon the known targets for pharmaceutical intervention, optimizing and combining well established therapies in novel and more effective ways. The cornerstone of the Cardiolynx’ approach is nitric oxide (NO) which is a multi-functional messenger in the cardiovascular system. By combining the effects of NO with those of other well-known molecules, either through fixed dose combinations or novel hybrid molecules. Cardiolynx intends to develop a broad portfolio of more efficient and convenient therapies to improve patient care and quality of life.